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INTRODUCTION:  Gastrointestinal  stromal  tumors  (GISTs)  are  the  most  common  mesenchymal  tumors  of
the  gastrointestinal  tract. Rarely,  GISTs  can  be located  in  mesentery,  retroperitoneal  space,  omentum  or
pancreas.  In  these  cases,  the  neoplasm  is deﬁned  as  “extra-gastrointestinal  stromal  tumors”  (EGISTs).
PRESENTATION  OF  CASE:  We  reported  a case  of  a  63-year-old  male  patient  diagnosed  by computer  tomog-
raphy  with  large  intraabdominal  tumor  with  vague  origin,  postoperatively  determined  as an  EGIST.  The
diagnosis  was conﬁrmed  by  immunohistochemical  study.  The  patient  had  multiple,  subcutaneous,  pain-
less  lipomas  localized  in the arms,  forearms,  thighs,  abdomen  and  thorax.  Because  of  the  family  history
and  the clinical  presentation  the disease  was  determined  as familial  multiple  lipomatosis  (FML).  We
performed  radical  tumor  resection  with  distal  pancreatectomy  and  splenectomy,  and  abdominoplasty,
removing  redundant  skin  and  underlying  subcutaneous  fat  tissue  with multiple  lipomas.
DISCUSSION:  FML  is  a rare  hereditary  benign  disease.  On  the other  hand,  only  few  cases  with  familial  GIST
have  been  reported.  In  cases  with  extensive  abdominal  involvement,  the  primary  origin  of EGIST  may  be
impossible  to determine  so  the  differential  diagnosis  is very  difﬁcult.
CONCLUSION:  Although  we  could  not  prove  correlation  between  the  observed  diseases,  they  are  extremely
rare  and  their combination  is unusual  which  makes  the  presented  case  valuable  and  interesting.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Although gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal tract, they
comprise less than 1% of all gastrointestinal tumors [1]. GISTs
are neoplasms arising from, or differentiating along, a line sim-
ilar to the cells of Cajal [2]. GISTs most commonly occur in the
stomach (60–70%), followed by the small intestine (20–30%), duo-
denum (4–5%), rectum (4–5%), colon (<2%) and esophagus(<1%)
[1,3]. Rarely, GISTs can be located in mesentery, retroperitoneal
space, omentum or pancreas [1,3,4]. These “extra-gastrointestinal
stromal tumors” (EGISTs) do not display connection to the wall or
the serosal surface of the stomach and the intestine [1–3].
Familial multiple lipomatosis (FML) is an extremely rare heredi-
tary benign disease (0002%) [5]. In FML, lipomas are usually painless
Abbreviations: GISTs, gastrointestinal stromal tumors; EGIST, extragastrointesti-
nal stromal tumor; FML, familial multiple lipomatosis; CT, computer tomography;
H&E, hematoxylin and eosin; NCCN, National Comprehensive Cancer Network.
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[5]. Sometimes these fatty tumors are numerous and large and
they have to be excised because patients cannot wear appropriate
clothing or interfere with joint movement [5,6].
We present a case of a FML-affected patient diagnosed with large
intraabdominal tumor with vague origin, postoperatively deter-
mined as an EGIST.
2. Presentation of case
A 63-year-old male was admitted with symptoms of intense
fatigue, abdominal discomfort and nausea without vomiting, con-
stipation, and fever up to 37.5 ◦C. Despite his long-term obesity
(body weight about 160 kg), in recent months the patient had
lost about 20 kg, but the circumference of the abdomen had been
increasing. The patient reported that he had multiple widespread
palpable nodules in his body but they were long standing and some
of them appeared during his childhood. His mother, some of his
cousins and his nephew had the same subcutaneous nodules.
The physical examination revealed a patient with obesity and
presence of multiple, subcutaneous, mobile and painless lipomas
varied in size and localized in the arms, forearms, thighs, abdomen
and thorax. The abdomen was without palpable pain, but with
http://dx.doi.org/10.1016/j.ijscr.2015.07.027
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Fig. 1. (A) Multiple subcutaneous lesions in the thorax, abdomen; (B) intraoperative view of the subcutaneous lipomas; (C) the patient after removal of the lipomas and
abdominoplasty.
visible and palpable lobular formations with soft consistence and
areas with dense texture (Fig. 1A).
Abdominal computed tomography (CT) demonstrated a soft
tissue heterogeneous formation, located under the diaphragm,
between the stomach and spleen, leading to compression of these
organs. Pancreas was with a normal visible head, but the rest
was not visualized. Routine laboratory tests revealed hemoglobin
119 g/l and leukocytes 17 × 109 cells/l. Tumor markers (CEA and CA
19–9) were within normal values.
The surgical procedure started with excision of the redundant
skin and underlying subcutaneous tissue with multiple lipomas
(Fig. 1B). After the laparotomy a rounded formation, attached to
the diaphragm was found. The tumor mass was localized behind
the stomach and under the transverse colon, involving the lesser
sac and lying on the mesentery of the small intestine, reaching the
entrance to the pelvic ﬂoor. There was no communication with the
guts. The total diameter of the tumor was about 40 cm.  The tumor
was heterogeneous, composed of solid area with diameter up to
15 cm and cystic zones. Multiple whitish round formations with
diameter up to 20 mm were isolated in addition to the main tumor.
The pancreatic body was milled by the tumor. So the presumable
clinical diagnosis was a pancreatic cystadenocarcinoma (Fig. 2). The
tumor was carefully extirpated. Splenectomy and distal pancreatic
resection were performed. The whole tumor weight was 10–12 kg.
The specimen was transected ex vivo—cystic parts of the tumor
were ﬁlled with liquid and necrotic tissues. Abdominoplasty was
performed (Fig. 1C).
Microscopically, the tumors were characterized by interlacing
bundles of elongated cells with spindle-shaped nuclei with ﬁbril-
lary collagenous background (Fig. 3). The nuclei of the tumor cells
in some areas showed a deﬁnite tendency to palisade and form
anuclear zones. Mitotic rate varied from 2 to 50 mitotic ﬁgures
per 50 high power ﬁelds in slides from different tumor forma-
tions. Foci of hemorrhages and necrosis were presented. Tumor
cells reached the peripancreatic fat tissue but did not inﬁltrate the
pancreatic parenchyma. Immunohistochemically the tumor cells
were CD117 and CD34 strongly positive, Cytokeratin AE1/3, Smooth
Muscle Actin, Desmin, and S-100 negative.
The surgical procedure lasted 4 h and 15 min. The postoperative
period was uneventful. The patient was discharged on the 9th post-
operative day. An adjuvant therapy with Imatinib was  initiated. The
patient was in good condition one year later.
3. Discussion
In 1846 Brodie reported multiple lipomatosis for the ﬁrst time,
but the hereditary aspect of FML  was shown in 1891 by Blashko
[5]. Inheritance of the disease is frequently by autosomal domi-
nant transmission, although cases with recessive inheritance have
also been reported [7]. Multiple lipomas, found on the trunk and
extremities with a relative sparing of the head and shoulders,
appearing mostly in the third decade of life and affecting several
members of a family, may  be highly suggestive of FML  [5,8], as
in our case. Typically for FML, our patient’s lipomas were painless
and they did not limit his daily activity [5–7]. The main treatment
of FML  is surgical excision [5]. The purpose usually is cosmetic but
sometimes there are functional disorders of the joints, extremi-
ties, etc. due to the nearby lipomas so their removal is required.
Other treatment options are liposuction and injection lipolysis
[5,9]. Because of the extreme obesity of our patient, we  decided
to perform abdominoplasty in order to reduce the subcutaneous
fatty tissues simultaneously with the removal of the lipomas.
In the presented case, we observed another rare disease—EGIST.
As we mentioned above, EGISTs occur outside the gastrointestinal
tract and in cases with extensive involvement of the abdominal
cavity the primary site of origin may  be impossible to determine
[10]. Only few cases with familial GIST have been reported and the
inheritance is autosomal dominant [10].
At present the origin of EGISTs remains controversial. EGISTs
and the cells of Cajal have some similar features like the expression
of CD117 and CD34 [2,3]. Yamamoto et al. reported that EGISTs
and GISTs probably have a similar origin because they show com-
parable KIT mutations [11]. Some authors suggest that GISTs and
EGISTs arise from the common precursor cell of cells of Cajal and
the smooth muscle cells of the intestine [2]. Other possibility is that
EGISTs are mural GISTs with loss of contact with the point of origin
due to an extensive extramural growth pattern [2].
Clinical presentation of EGISTs is non speciﬁc and variable
depending on the tumor size and localization.[1,2,10] The CT and
magnetic resonance imaging are the ﬁrst choice of diagnostic meth-
ods [1,4]. The endoscopic studies and endoscopic ultrasound are
diagnostic options for gastric and intestinal GISTs or the connec-
tion of EGISTs with the guts can be excluded with them [4]. Positron
emission tomography is an additional option [1,4].
Unique microscopic features (fusiform, epithelioid or mixed
type) and immunohistochemical techniques (CD-117, CD34, actin,
desmin, S-100 and ki-67) are very important to conﬁrm the diagno-
sis. Mitotic index have to be determined in the most active regions
and margins status. Different types of mutations can be found in
KIT and PDGFRA genes which encode a receptor tyrosine kinases
type III [1,2,4,10].
Risk stratiﬁcation of GISTs according to Miettinen et al.,
Fletcher’s classiﬁcation and UICC classiﬁcation is based on mitotic
index, tumor size and localization [1–4,10]. But none of these classi-
ﬁcations include the EGISTs. Achieved resection margins (R0 or R1)
and capsule rupture are other prognostic factors [10]. However,
the available data in literature regarding the prognosis of EGISTs
are still rather limited [2,10].
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Fig. 2. (A) Intraoperative view of the solid part of the tumor; (B) the patient’s abdominal cavity after radical tumor extirpation.
Fig. 3. Macroscopic and microscopic pathological view of the tumor (H&E —hematoxylin and eosin).
Surgical resection is the standard treatment of EGISTs [1,2,4,10].
The aim is to achieve R0 resection related to 48–65% 5-year sur-
vival [1]. If adjacent organs are involved, en bloc resections have to
be performed [1,4,10]. Intraperitoneal rupture or excessive bleed-
ing is associated with a high risk of postoperative recurrence [10].
Because of the rarity of metastases of GIST in lymph nodes, system-
atic lymphadenectomy is not a standard procedure [1,4,10].
Despite the fact that complete resection is feasible in most local-
ized GIST cases, there is still a recurrence rate of up to 50% according
to some studies [4]. So the opportunity of targeted medical therapy
of GISTs by tyrosine kinase inhibitors is very useful [4,10,12,13].
According to the NCCN guidelines, neoadjuvant therapy is recom-
mended for GISTs that are marginally resectable or resectable with
risk of signiﬁcant morbidity [4,13]. Adjuvant treatment for low-risk
patients is not indicated [4,12,13]. Cases with capsule rupture are
indicated for targeted therapy too [4]. However, data about targeted
treatment for EGISTs is still limited [2].
4. Conclusion
We  report a case of a patient with two rare diseases—FML and
EGIST, misinterpreted macroscopically as a pancreatic cystade-
nocarcinoma. The radical resection of EGIST is the treatment of
choice and therapy with Imatinib was performed because of the
revealed high-risk tumor variant. Abdominoplasty was the option
to improve the patient’s quality of life, removing redundant skin
and underlying subcutaneous fat tissue with multiple lipomas.
Although we could not prove correlation between the observed
diseases, they are extremely rare and their combination is unusual
which makes the presented case valuable and interesting.
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